QureBio develops bispecific and multispecific antibody and protein therapeutics using proprietary platforms including I2T and T‑cell and NK‑cell engager platforms. Its pipeline includes Q‑1802 (Claudin18.2/PD‑L1 bispecific) with Phase II enrollment nearly complete and preparations for Phase III in China, Q‑1801 (SIRPα/PD‑L1 bispecific) poised to begin clinical studies, and a PD‑1 antibody‑cytokine fusion candidate. The company has regulatory clearances to initiate clinical trials in both China and the United States for multiple candidates. QureBio was founded in 2017 and is based in Shanghai. It has established collaborations with BRL Medicine, BioMap, Hengrui Pharma, and Precision Scientific to co‑develop therapies. The recent financing will be used to accelerate clinical trials and advance its core pipeline globally. QureBio is dedicated to the development of innovative antibody drugs. The company is invested in and incubated by Viva BioInnovator. In December 2021 QureBio announced it had completed nearly 200 Million RMB in a Series B financing. The Series B round was led by BOCOM International Holdings. Other participants in the round included Guoshun Investment, Oriza Holdings, Lihe Hongxin Venture Investment, Tianfu Sanjiang Capital, Spinnotec and Longmen Capital.

Total raised

$45M

Funding rounds

2

Latest round

Series C

Latest activity

Jun 2025